ReviewCancers2026
Gut Dysbiosis Serine-Glycine Metabolism and Glioblastoma: Exploring Therapeutic Opportunities.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut-brain axis is a central regulatory network linking dietary habits, metabolic homeostasis, and brain function through bidirectional communication among the intestine, microbiota, and central nervous system. Acting as a key mediator, the gut microbiota translates environmental and nutritional factors into systemic outcomes that influence both health and disease. Within this context, serine and glycine metabolism emerges as a critical yet underexplored hub connecting microbial activity with brain regulation. Changes in gut microbial composition can profoundly affect host one-carbon metabolism and amino acid availability, shaping systemic physiology and neural processes. In this review, we outline a biochemical framework in which gut microbiota alterations influence brain and liver serine/glycine (ser/gly) metabolism, driving the hepatic production of secondary metabolites, including taurine-conjugated bile acids. We delineate how gut-brain axis pathways orchestrate systemic and neural functions, and highlight glioblastoma (GBM) as a pathological context where hijacked serine-glycine metabolism fuels tumor growth, stemness, and therapy resistance. By focusing on the interplay between gut microbiota, ser/gly metabolism, and brain tumor biology, this review offers a cohesive perspective on translational interventions. Glycine-centered pathways emerge as promising targets to modulate the gut-brain-tumor axis, opening new avenues to influence GBM progression and enhance therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.